Optimizing Commercial Distribution As You Prepare To Launch Your CGT

When launching new cell and gene therapies (CGTs), biopharma manufacturers often face significant hurdles in getting these complex treatments to patients. An effective commercial distribution strategy is crucial for success, and anticipating challenges before commercialization can create a smoother transition from clinical research to a commercial program. Key priorities for manufacturers should include determining the most effective channel strategy for patient access, expanding into new sites of care as the market grows, setting up infrastructure that supports sites of care, and maintaining the flexibility to adapt the strategy to the changing needs of various stakeholders.

Explore how to overcome common obstacles during the move into commercial distribution and ensure your revolutionary therapies reach patients efficiently.